TENX — Tenax Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$1.82
+$0.02 (+1.11%)
Tenax Therapeutics Inc (TENX) is a biotechnology company listed on NASDAQ. It is led by Christopher T. Giordano, based in 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517, with about 4 employees. Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Latest reported TENX revenue for 2025-09-30 was $0. Net income was -$37.1M. TENX currently screens at market cap $24.1M and trailing P/E 3.4.
Use this TENX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TENX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TENX SEC filings page. Lician reads the product cache first so this HTML stays unique to Tenax Therapeutics Inc even when a live quote feed is slow.
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
TENX Key Statistics
Market Cap
$24.06M
Volume
14.29M
Previous Close
$1.85
Day Range
$2.08 – $2.43
P/E Ratio
3.43
EPS
-$1.15
Revenue
$0.00
Net Income
-$17.60M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
4
TENX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$17.60M | -$7.71M | -$11.05M | -$32.47M |
| EPS (Diluted) | -$1.15 | -$31.04 | $0.00 | $0.00 |
Total Assets
$96.69M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$94.90M
Operating Cash Flow
-$14.81M
Free Cash Flow
$0.00
Tenax Therapeutics Inc Company Information
- CEO, President & Director
- Christopher T. Giordano
- Headquarters
- 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517
- Website
- www.tenaxthera.com
- Phone
- 919 855 2100
- IPO / Founded
- 1997-01-02
- Sector
- Healthcare
- Industry
- Biotechnology